Patents by Inventor Freek Johannes Maria Hoeben

Freek Johannes Maria Hoeben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11859021
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 2, 2024
    Assignees: Icahn School of Medicine at Mount Sinai, Trained Therapeutix Discovery, Inc.
    Inventors: Henricus Marie Janssen, Freek Johannes Maria Hoeben, Bas Van Genabeek, Serge Hendrikus Mathijs Sontjens, Willem J. M. Mulder
  • Publication number: 20230144534
    Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit having a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine having a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of the Construct.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 11, 2023
    Applicants: TAGWORKS PHARMACEUTICALS B.V., SYNCOM B.V.
    Inventors: Marc Stefan ROBILLARD, Wolter TEN HOEVE, Freek Johannes Maria HOEBEN, Ronny Mathieu VERSTEEGEN, Hendricus Marie JANSSEN, Arthur Henry Antoon Marie VAN ONZEN, Raffaella ROSSIN
  • Patent number: 11617799
    Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit having a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine having a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of the Construct.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 4, 2023
    Assignees: TAGWORKS PHARMACEUTICALS B.V., SYNCOM B.V.
    Inventors: Marc Stefan Robillard, Wolter Ten Hoeve, Freek Johannes Maria Hoeben, Ronny Mathieu Versteegen, Hendricus Marie Janssen, Arthur Henry Antoon Marie Van Onzen, Raffaella Rossin
  • Publication number: 20220356169
    Abstract: Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield and high click release yields. In some of several other aspects, the invention relates to combinations and kits having the tetrazines and a dienophile, preferably a trans-cyclooctene. In another aspect, the compounds, combinations, and kits are for use as a medicament.
    Type: Application
    Filed: June 17, 2020
    Publication date: November 10, 2022
    Applicant: Tagworks Pharmaceuticals B.V.
    Inventors: Marc Stefan ROBILLARD, Freek Johannes Maria HOEBEN, Raffaella ROSSIN, Ronny Mathieu VERSTEEGEN, Henricus Marie JANSSEN
  • Publication number: 20220332762
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: October 20, 2022
    Inventors: Henricus Marie JANSSEN, Freek Johannes Maria HOEBEN, Bas VAN GENABEEK, Serge Hendrikus Mathijs SONTJENS, Willem J. M. MULDER
  • Publication number: 20210299286
    Abstract: Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield in vivo and high click release yields. In one aspect, the invention relates to kits having the tetrazines and a dienophile, preferably a trans-cyclooctene. In another aspect, the kits of the invention are for use as a medicament.
    Type: Application
    Filed: May 6, 2019
    Publication date: September 30, 2021
    Applicant: Tagworks Pharmaceuticals B.V.
    Inventors: Marc Stefan ROBILLARD, Ronny Mathieu VERSTEEGEN, Raffaella ROSSIN, Freek Johannes Maria HOEBEN, Sander Izaak VAN KASTEREN, Michel Johan VAN DE GRAAFF
  • Publication number: 20190247513
    Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit comprising a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine comprising a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of said Construct.
    Type: Application
    Filed: June 27, 2017
    Publication date: August 15, 2019
    Applicant: Tagworks Pharmaceuticals B.V.
    Inventors: Marc Stefan ROBILLARD, Wolter TEN HOEVE, Freek Johannes Maria HOEBEN, Ronny Mathieu VERSTEEGEN, Hendricus Marie JANSSEN, Arthur Henry Antoon Marie VAN ONZEN, Raffaella ROSSIN
  • Publication number: 20160151505
    Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
    Type: Application
    Filed: May 16, 2012
    Publication date: June 2, 2016
    Applicant: KONINKLIJKE PHILIPS N.V.
    Inventors: Marc Stefan Robillard, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin, Freek Johannes Maria Hoeben